O	0	3	The
O	4	16	relationship
O	17	24	between
B-intervention	25	36	circulating
I-intervention	37	43	lipids
O	44	47	and
O	48	54	breast
O	55	61	cancer
O	62	66	risk
O	66	67	:
O	68	69	A
O	70	79	Mendelian
O	80	93	randomization
O	94	99	study
O	99	100	.

O	101	102	A
O	103	109	number
O	110	112	of
O	113	128	epidemiological
O	129	132	and
O	133	140	genetic
O	141	148	studies
O	149	153	have
O	154	163	attempted
O	164	166	to
O	167	176	determine
O	177	184	whether
O	185	191	levels
O	192	194	of
O	195	206	circulating
O	207	213	lipids
O	214	217	are
O	218	228	associated
O	229	233	with
O	234	239	risks
O	240	242	of
O	243	250	various
O	251	258	cancers
O	258	259	,
O	260	269	including
O	270	276	breast
O	277	283	cancer
O	284	285	(
O	285	287	BC
O	287	288	)
O	288	289	.

O	290	297	However
O	297	298	,
O	299	301	it
O	302	309	remains
O	310	317	unclear
O	318	325	whether
O	326	327	a
O	328	334	causal
O	335	347	relationship
O	348	354	exists
O	355	362	between
O	363	369	lipids
O	370	373	and
O	374	376	BC
O	376	377	.

O	378	380	If
O	381	391	alteration
O	392	394	of
O	395	400	lipid
O	401	407	levels
O	408	412	also
O	413	420	reduced
O	421	425	risk
O	426	428	of
O	429	431	BC
O	431	432	,
O	433	437	this
O	438	443	could
O	444	451	present
O	452	453	a
O	454	460	target
O	461	464	for
O	465	472	disease
O	473	483	prevention
O	483	484	.

O	485	489	This
O	490	495	study
O	496	501	aimed
O	502	504	to
O	505	511	assess
O	512	513	a
O	514	523	potential
O	524	530	causal
O	531	543	relationship
O	544	551	between
O	552	559	genetic
O	560	568	variants
O	569	579	associated
O	580	584	with
O	585	591	plasma
O	592	597	lipid
O	598	604	traits
O	605	606	(
O	606	610	high
O	610	611	-
O	611	618	density
O	619	630	lipoprotein
O	630	631	,
O	632	635	HDL
O	635	636	;
O	637	640	low
O	640	641	-
O	641	648	density
O	649	660	lipoprotein
O	660	661	,
O	662	665	LDL
O	665	666	;
O	667	680	triglycerides
O	680	681	,
O	682	685	TGs
O	685	686	)
O	687	691	with
O	692	696	risk
O	697	700	for
O	701	703	BC
O	704	709	using
O	710	719	Mendelian
O	720	733	randomization
O	734	735	(
O	735	737	MR
O	737	738	)
O	738	739	.

O	740	744	Data
O	745	749	from
O	750	756	genome
O	756	757	-
O	757	761	wide
O	762	773	association
O	774	781	studies
O	782	784	in
O	785	787	up
O	788	790	to
B-total-participants	791	794	215
I-total-participants	794	795	,
I-total-participants	795	798	551
O	799	811	participants
O	812	816	from
O	817	820	the
O	821	828	Million
O	829	836	Veteran
O	837	844	Program
O	845	846	(
O	846	849	MVP
O	849	850	)
O	851	855	were
O	856	860	used
O	861	863	to
O	864	873	construct
O	874	881	genetic
O	882	893	instruments
O	894	897	for
O	898	904	plasma
O	905	910	lipid
O	911	917	traits
O	917	918	.

O	919	922	The
O	923	929	effect
O	930	932	of
O	933	938	these
O	939	950	instruments
O	951	953	on
O	954	956	BC
O	957	961	risk
O	962	965	was
O	966	975	evaluated
O	976	981	using
O	982	989	genetic
O	990	994	data
O	995	999	from
O	1000	1003	the
O	1004	1008	BCAC
O	1009	1010	(
O	1010	1016	Breast
O	1017	1023	Cancer
O	1024	1035	Association
O	1036	1046	Consortium
O	1046	1047	)
O	1048	1053	based
O	1054	1056	on
B-intervention-participants	1057	1060	122
I-intervention-participants	1060	1061	,
I-intervention-participants	1061	1064	977
O	1065	1067	BC
O	1068	1073	cases
O	1074	1077	and
B-control-participants	1078	1081	105
I-control-participants	1081	1082	,
I-control-participants	1082	1085	974
B-control	1086	1094	controls
O	1094	1095	.

O	1096	1101	Using
O	1102	1104	MR
O	1104	1105	,
O	1106	1108	we
O	1109	1117	observed
O	1118	1122	that
O	1123	1124	a
O	1125	1126	1
O	1126	1127	-
O	1127	1135	standard
O	1135	1136	-
O	1136	1145	deviation
O	1146	1157	genetically
O	1158	1168	determined
O	1169	1177	increase
O	1178	1180	in
B-outcome	1181	1184	HDL
I-outcome	1185	1191	levels
O	1192	1194	is
O	1195	1205	associated
O	1206	1210	with
O	1211	1213	an
O	1214	1223	increased
O	1224	1228	risk
O	1229	1232	for
O	1233	1236	all
O	1237	1240	BCs
O	1241	1242	(
O	1242	1245	HDL
O	1245	1246	:
O	1247	1249	OR
O	1250	1251	[
O	1251	1255	odds
O	1256	1261	ratio
O	1261	1262	]
O	1263	1264	=
O	1265	1266	1
O	1266	1267	.
O	1267	1269	08
O	1269	1270	,
O	1271	1273	95
O	1273	1274	%
O	1275	1285	confidence
O	1286	1294	interval
O	1295	1296	[
O	1296	1298	CI
O	1298	1299	]
O	1300	1301	=
O	1302	1303	1
O	1303	1304	.
O	1304	1306	04
O	1306	1307	-
O	1307	1308	1
O	1308	1309	.
O	1309	1311	13
O	1311	1312	,
O	1313	1314	P
O	1315	1316	<
O	1317	1318	0
O	1318	1319	.
O	1319	1322	001
O	1322	1323	)
O	1323	1324	.

O	1325	1338	Multivariable
O	1339	1341	MR
O	1342	1350	analysis
O	1350	1351	,
O	1352	1357	which
O	1358	1366	adjusted
O	1367	1370	for
O	1371	1374	the
O	1375	1382	effects
O	1383	1385	of
O	1386	1389	LDL
O	1389	1390	,
O	1391	1394	TGs
O	1394	1395	,
B-outcome	1396	1400	body
I-outcome	1401	1405	mass
I-outcome	1406	1411	index
I-outcome	1412	1413	(
I-outcome	1413	1416	BMI
I-outcome	1416	1417	)
O	1417	1418	,
O	1419	1422	and
O	1423	1426	age
O	1427	1429	at
O	1430	1438	menarche
O	1438	1439	,
O	1440	1452	corroborated
O	1453	1457	this
O	1458	1469	observation
O	1470	1473	for
O	1474	1477	HDL
O	1478	1479	(
O	1479	1481	OR
O	1482	1483	=
O	1484	1485	1
O	1485	1486	.
O	1486	1488	06
O	1488	1489	,
O	1490	1492	95
O	1492	1493	%
O	1494	1496	CI
O	1497	1498	=
O	1499	1500	1
O	1500	1501	.
O	1501	1503	03
O	1503	1504	-
O	1504	1505	1
O	1505	1506	.
O	1506	1508	10
O	1508	1509	,
O	1510	1511	P
O	1512	1513	=
O	1514	1515	4
O	1515	1516	.
O	1516	1517	9
O	1518	1519	×
O	1520	1522	10
O	1522	1523	-
O	1523	1524	4
O	1524	1525	)
O	1526	1529	and
O	1530	1534	also
O	1535	1540	found
O	1541	1542	a
O	1543	1555	relationship
O	1556	1563	between
B-outcome	1564	1567	LDL
I-outcome	1568	1571	and
I-outcome	1572	1574	BC
I-outcome	1575	1579	risk
O	1580	1581	(
O	1581	1583	OR
O	1584	1585	=
O	1586	1587	1
O	1587	1588	.
O	1588	1590	03
O	1590	1591	,
O	1592	1594	95
O	1594	1595	%
O	1596	1598	CI
O	1599	1600	=
O	1601	1602	1
O	1602	1603	.
O	1603	1605	01
O	1605	1606	-
O	1606	1607	1
O	1607	1608	.
O	1608	1610	07
O	1610	1611	,
O	1612	1613	P
O	1614	1615	=
O	1616	1617	0
O	1617	1618	.
O	1618	1620	02
O	1620	1621	)
O	1621	1622	.

O	1623	1625	We
O	1626	1629	did
O	1630	1633	not
O	1634	1641	observe
O	1642	1643	a
O	1644	1654	difference
O	1655	1657	in
O	1658	1663	these
O	1664	1677	relationships
O	1678	1682	when
O	1683	1693	stratified
O	1694	1696	by
O	1697	1703	breast
O	1704	1709	tumor
O	1710	1718	estrogen
O	1719	1727	receptor
O	1728	1729	(
O	1729	1731	ER
O	1731	1732	)
O	1733	1739	status
O	1739	1740	.

O	1741	1743	We
O	1744	1752	repeated
O	1753	1757	this
O	1758	1766	analysis
O	1767	1772	using
O	1773	1780	genetic
O	1781	1789	variants
O	1790	1801	independent
O	1802	1804	of
O	1805	1808	the
O	1809	1816	leading
O	1817	1828	association
O	1829	1831	at
O	1832	1836	core
O	1837	1840	HDL
O	1841	1848	pathway
O	1849	1854	genes
O	1855	1858	and
O	1859	1864	found
O	1865	1869	that
O	1870	1875	these
O	1876	1884	variants
O	1885	1889	were
O	1890	1894	also
O	1895	1905	associated
O	1906	1910	with
O	1911	1915	risk
O	1916	1919	for
O	1920	1923	BCs
O	1924	1925	(
O	1925	1927	OR
O	1928	1929	=
O	1930	1931	1
O	1931	1932	.
O	1932	1934	11
O	1934	1935	,
O	1936	1938	95
O	1938	1939	%
O	1940	1942	CI
O	1943	1944	=
O	1945	1946	1
O	1946	1947	.
O	1947	1949	06
O	1949	1950	-
O	1950	1951	1
O	1951	1952	.
O	1952	1954	16
O	1954	1955	,
O	1956	1957	P
O	1958	1959	=
O	1960	1961	1
O	1961	1962	.
O	1962	1963	5
O	1964	1965	×
O	1966	1968	10
O	1968	1969	-
O	1969	1970	6
O	1970	1971	)
O	1971	1972	,
O	1973	1982	including
O	1983	1988	locus
O	1988	1989	-
O	1989	1997	specific
O	1998	2010	associations
O	2011	2013	at
O	2014	2019	ABCA1
O	2020	2021	(
O	2021	2024	ATP
O	2025	2032	Binding
O	2033	2041	Cassette
O	2042	2051	Subfamily
O	2052	2053	A
O	2054	2060	Member
O	2061	2062	1
O	2062	2063	)
O	2063	2064	,
O	2065	2069	APOE
O	2069	2070	-
O	2070	2075	APOC1
O	2075	2076	-
O	2076	2081	APOC4
O	2081	2082	-
O	2082	2087	APOC2
O	2088	2089	(
O	2089	2104	Apolipoproteins
O	2105	2106	E
O	2106	2107	,
O	2108	2110	C1
O	2110	2111	,
O	2112	2114	C4
O	2114	2115	,
O	2116	2119	and
O	2120	2122	C2
O	2122	2123	)
O	2123	2124	,
O	2125	2128	and
O	2129	2133	CETP
O	2134	2135	(
O	2135	2146	Cholesteryl
O	2147	2152	Ester
O	2153	2161	Transfer
O	2162	2169	Protein
O	2169	2170	)
O	2170	2171	.

O	2172	2174	In
O	2175	2183	addition
O	2183	2184	,
O	2185	2187	we
O	2188	2193	found
O	2194	2202	evidence
O	2203	2207	that
O	2208	2215	genetic
O	2216	2225	variation
O	2226	2228	at
O	2229	2232	the
O	2233	2236	ABO
O	2237	2242	locus
O	2243	2245	is
O	2246	2256	associated
O	2257	2261	with
O	2262	2266	both
O	2267	2272	lipid
O	2273	2279	levels
O	2280	2283	and
O	2284	2286	BC
O	2286	2287	.

O	2288	2295	Through
O	2296	2304	multiple
O	2305	2316	statistical
O	2317	2327	approaches
O	2327	2328	,
O	2329	2331	we
O	2332	2341	minimized
O	2342	2345	and
O	2346	2352	tested
O	2353	2356	for
O	2357	2360	the
O	2361	2372	confounding
O	2373	2380	effects
O	2381	2383	of
O	2384	2394	pleiotropy
O	2395	2398	and
O	2399	2409	population
O	2410	2424	stratification
O	2425	2427	on
O	2428	2431	our
O	2432	2440	analysis
O	2440	2441	;
O	2442	2449	however
O	2449	2450	,
O	2451	2454	the
O	2455	2463	possible
O	2464	2473	existence
O	2474	2476	of
O	2477	2485	residual
O	2486	2496	pleiotropy
O	2497	2500	and
O	2501	2515	stratification
O	2516	2523	remains
O	2524	2525	a
O	2526	2536	limitation
O	2537	2539	of
O	2540	2544	this
O	2545	2550	study
O	2550	2551	.

O	2552	2554	We
O	2555	2563	observed
O	2564	2568	that
O	2569	2580	genetically
O	2581	2589	elevated
O	2590	2596	plasma
O	2597	2600	HDL
O	2601	2604	and
O	2605	2608	LDL
O	2609	2615	levels
O	2616	2622	appear
O	2623	2625	to
O	2626	2628	be
O	2629	2639	associated
O	2640	2644	with
O	2645	2654	increased
O	2655	2657	BC
O	2658	2662	risk
O	2662	2663	.

O	2664	2670	Future
O	2671	2678	studies
O	2679	2682	are
O	2683	2691	required
O	2692	2694	to
O	2695	2705	understand
O	2706	2709	the
O	2710	2719	mechanism
O	2720	2730	underlying
O	2731	2735	this
O	2736	2744	putative
O	2745	2751	causal
O	2752	2764	relationship
O	2764	2765	,
O	2766	2770	with
O	2771	2774	the
O	2775	2779	goal
O	2780	2782	of
O	2783	2793	developing
O	2794	2803	potential
O	2804	2815	therapeutic
O	2816	2826	strategies
O	2827	2832	aimed
O	2833	2835	at
O	2836	2844	altering
O	2845	2848	the
O	2849	2860	cholesterol
O	2860	2861	-
O	2861	2869	mediated
O	2870	2876	effect
O	2877	2879	on
O	2880	2882	BC
O	2883	2887	risk
O	2887	2888	.
